Dossier assessment

Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A21-151
Last updated

Report documents

  1. Extract of dossier assessment

    Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 383 kB, EN, not accessible
  2. Dossier assessment

    Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 599 kB, DE, not accessible

Dossier assessment

Indication:

Add-on therapy for patients from 6 years and above with relapsing remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA)

Result of dossier assessment:

Added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2022-05-20 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A21-151
Commission
Commission awarded on 30.11.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Immune system and infections
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-150
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-58
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Mepolizumab - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-03
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Mepolizumab (hypereosinophilic syndrome) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-152
    Last updated

    Status: Commission completed

  5. Addendum

    Mepolizumab (eosinophilic granulomatosis with polyangiitis) – Addendum to Commission A21-151

    Project no.
    A22-43
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Mepolizumab (COPD) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A26-25
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form